OrthoPediatrics

OrthoPediatrics Corp. is an orthopedic company, which engages in the design, development, and marketing of anatomically appropriate implants and devices for children with orthopedic conditions. It offers products relating to trauma and deformity, scoliosis, and sports medicine and other procedures. The company was founded by Erin Springer Yount and Nick A. Deeter in August 2006 and is headquartered in Warsaw, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

OrthoPediatrics achieves record revenue growth and eyes international expansion

OrthoPediatrics delivered strong financial performance in 2022, achieving profitability and record revenue growth despite challenges. With a focus on new product launches, international expansion, and surgeon training, the company is well-positioned for continued growth and profitability.

OrthoPediatrics reports robust Q1 earnings, eyes international growth opportunities

OrthoPediatrics had a strong Q1 2023, with increased revenue guidance for the full year. The company remains cautiously optimistic due to staffing dynamics. Focus on new product development, acquisitions, and addressing digital needs of children's hospitals highlight growth strategies.

OrthoPediatrics achieves record Q2 performance amidst growth challenges

OrthoPediatrics delivered strong Q2 results with record child assistance and revenue growth, driven by trauma, deformity, and international segments.
While facing challenges like atypical growth patterns and delays in product launches, the company is well-positioned to capitalize on opportunities in enabling technologies and international expansion.
The focus on long-term growth drivers and strategic acquisitions underscores OrthoPediatrics' commitment to sustainable growth and innovation in pediatric orthopedics.
Overall, OrthoPediatrics' performance highlights operational efficiency, market demand, and a clear path for future growth and expansion.

OrthoPediatrics achieves record revenue in Q3 2023, eyes continued growth

OrthoPediatrics reported strong financial performance in Q3 2023, with record revenue and EBITDA, positioning the company for future growth. Despite challenges in certain segments, opportunities in new product launches, international expansion, and surgeon training initiatives offer avenues for continued success. The company's positive outlook and robust pipeline indicate a promising trajectory for OrthoPediatrics.

OrthoPediatrics achieves record revenue and EBITDA, eyes international expansion

OrthoPediatrics delivered strong financial performance in 2023, setting revenue and EBITDA records. The company's strategic focus on sustainable growth, profitability, and diversification positions it well for future success.

OrthoPediatrics reports robust Q1 growth, raises full-year revenue guidance

OrthoPediatrics demonstrated strong performance in Q1 2024 with significant growth in patients helped, revenue, and key business segments. While facing challenges such as an EBITDA loss and increased expenses, the company's focus on growth, new product launches, and financial targets positions it well for the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Fourth Quarter 2022 Revenue Increased 25% Year-over-Year Full Year 2022 Revenue Increased 25% Year-over-Year

OrthoPediatrics Corp. Reports Fourth Quarter and Full Year 2022 Financial Results

OrthoPediatrics (KIDS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OrthoPediatrics (KIDS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

WARSAW, Ind., Feb. 14, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its fourth quarter and full year 2022 financial results on Tuesday, February 28, 2023, after the market closes. OrthoPediatrics will host a conference call on Wednesday, March 1, 2023, at 8:00 a.m. ET to discuss the results.

OrthoPediatrics Corp. to Report Fourth Quarter and Full Year 2022 Financial Results on March 1, 2023

WARSAW, Ind., Feb. 01, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the publication of an Environmental, Social, and Governance (“ESG”) summary report. The report highlights how the Company's commitment to diversity, inclusion and ethics underscores its mission to transform the lives of children with orthopedic conditions and provides a baseline of key ESG performance metrics.

OrthoPediatrics Corp. Publishes Environmental, Social, and Governance (“ESG”) Summary Report

Chefs' Warehouse

Alphabet

Hims & Hers Health

Intuitive Surgical

TipRanks analyst ranking service pinpoints Wall Street's best-performing stocks, including Alphabet & Intuitive Surgical

Top Wall Street analysts like these stocks amid easing inflation

WARSAW, Ind., Jan. 09, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced preliminary unaudited net revenue for the fourth quarter and full year ended December 31, 2022, and provided 2023 financial guidance.

OrthoPediatrics Corp. Announces Preliminary Unaudited Net Revenue for the Fourth Quarter & Full Year 2022, Provides Financial Outlook for 2023

WARSAW, Ind., Jan. 06, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the establishment of its direct sales organization in Germany. OrthoPediatrics GmbH, commencing operations on January 1, 2023. OrthoPediatrics' first direct international organization represents an expanding commitment to support pediatric orthopedics in international markets.

OrthoPediatrics Corp. Establishes Direct Sales Organization in Germany

OrthoPediatrics is a niche operator within the paediatrics segment of the orthopaedics market. As such, it is a key differential for equity investors looking to position within this segment, offering a diversified source of potential value.

OrthoPediatrics: Differentiated Offering In Paediatric Orthopaedics

Continues IPOS Corporate Partnership as Double Diamond Sponsor Continues IPOS Corporate Partnership as Double Diamond Sponsor

OrthoPediatrics Corp. to Host Educational and Networking Events at 18th Annual International Pediatric Orthopaedic Symposium (IPOS)

WARSAW, Ind., Nov. 04, 2022 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that Dave Bailey, President & Chief Executive Officer, and Fred Hite, Chief Operating Officer and Chief Financial Officer, are scheduled to participate in fireside chats at two upcoming investor conferences.

OrthoPediatrics to Participate in Upcoming November Conferences

OrthoPediatrics Corp (NASDAQ:KIDS ) Q3 2022 Earnings Conference Call November 1, 2022 8:00 AM ET Company Participants Emma Poalillo - Gilmartin Group David Bailey - President, CEO & Director Fred Hite - CFO, Principal Financial & Accounting Officer, COO and Director Conference Call Participants Matthew O'Brien - Piper Sandler & Co. Anton Heldmann - Stifel, Nicolaus & Company Ryan Zimmerman - BTIG Samuel Brodovsky - Truist Securities Michael Matson - Needham & Company Operator Good morning, and welcome to OrthoPediatrics Corporation Third Quarter 2022 Earnings Conference Call. [Operator Instructions].

OrthoPediatrics Corp (KIDS) Q3 2022 Earnings Call Transcript

OrthoPediatrics (KIDS) delivered earnings and revenue surprises of 73.68% and 4.09%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

OrthoPediatrics (KIDS) Reports Q3 Loss, Lags Revenue Estimates

Third Quarter 2022 Record Revenue Increased 39% Year-over-Year Third Quarter 2022 Record Revenue Increased 39% Year-over-Year

OrthoPediatrics Corp. Reports Third Quarter 2022 Financial Results and Updates 2022 Revenue Guidance

WARSAW, Ind., Oct. 20, 2022 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the appointment of Jimmy D. McDonald to its board of directors, effective October 18, 2022.

OrthoPediatrics Corp. Announces Appointment of Jimmy D. McDonald to Board of Directors

WARSAW, Ind., Oct. 18, 2022 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its third quarter 2022 financial results on Monday, October 31, 2022, after the market closes. OrthoPediatrics will host a conference call on Tuesday, November 1, 2022, at 8:00 a.m. ET to discuss the results.

OrthoPediatrics Corp. to Report Third Quarter 2022 Financial Results on November 1, 2022

Malibu Boats

Photronics

Douglas Dynamics

Stratasys

Varex Imaging

Generally speaking, you want to keep your portfolio tied largely to blue-chip stocks.  However, on occasion, your portfolio should also include cheap small-cap stocks.

7 Small-Cap Stocks That Are Too Cheap to Ignore

The average of price targets set by Wall Street analysts indicates a potential upside of 31.6% in OrthoPediatrics (KIDS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See a 32% Upside in OrthoPediatrics (KIDS): Can the Stock Really Move This High?

COMPASS Pathways

Nano-X Imaging

Here's why OrthoPediatrics, Compass Pathways, and Nano-X Imaging look like great stocks.

3 Stocks to Buy and Hold for the Long Term

WARSAW, Ind., Aug. 18, 2022 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the company will present at the upcoming Inaugural Gilmartin Group Emerging Growth Company Showcase, taking place virtually. Members of management are scheduled to present on Wednesday, August 31, 2022 at 2:00pm Eastern Time.

OrthoPediatrics to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase

WARSAW, Ind., Aug. 15, 2022 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the closing of its underwritten public offering of 1,091,250 shares of its common stock at a public offering price of $55.00 per share and in lieu of common stock, pre-funded warrants to purchase up to 1,525,000 shares of common stock at an offering price of $54.99975 per pre-funded warrant and with an exercise price of $0.00025 per share.  The offering represented the exercise in full by the underwriters of their option to purchase additional shares of common stock on the same terms and conditions.

OrthoPediatrics Corp. Announces Closing of its Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

WARSAW, Ind., Aug. 10, 2022 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced it has commenced an underwritten public offering of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. OrthoPediatrics expects to grant underwriters a 30-day option to purchase additional shares of its common stock. The offering is subject to market and other customary closing conditions, and there can be no assurance as to whether or when the offering may be completed. All of the shares of common stock and the pre-funded warrants to be sold in the offering are to be offered by OrthoPediatrics.

OrthoPediatrics Corp. Announces Proposed Offering of Common Stock and Pre-Funded Warrants

OrthoPediatrics Corp. (NASDAQ:KIDS ) Q2 2022 Earnings Conference Call August 4, 2022 8:00 AM ET Company Participants Matt Bacso - IR, Gilmartin Group David Bailey - President and Chief Executive Officer Fred Hite - Chief Financial Officer and Chief Operating Officer Conference Call Participants Ryan Zimmerman - BTIG David Saxon - Needham & Company Sam Bardowski - Truist Daniel Stauder - JMP Securities Operator Good morning, and welcome to OrthoPediatrics Corporation Second Quarter 2022 Earnings Conference Call. At this time, all participants are in listen-only mode.

OrthoPediatrics Corp. (KIDS) CEO David Bailey on Q2 2022 Results - Earnings Call Transcript

Second Quarter 2022 Record Revenue Increased 23% Year-over-Year Second Quarter 2022 Record Adjusted EBITDA of $2.1 million

OrthoPediatrics Corp. Reports Second Quarter 2022 Financial Results and Increases 2022 Revenue Guidance

Novavax

 Pliant Therapeutics

Here's why we like Novavax, Orthopediatrics, and Pliant Therapeutics.

2022 Roundtable: Our Favorite Picks Right Now

WARSAW, Ind., July 21, 2022 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today that the Company is scheduled to release its second quarter 2022 financial results on Wednesday, August 3, 2022, after the market closes. OrthoPediatrics will host a conference call on Thursday, August 4, 2022, at 8:00 a.m. ET to discuss the results.

News for OrthoPediatrics Stock (KIDS)